All In Biotech

Drug Trial Radar · NCT00419263

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

A Phase II, Multicenter, Randomized, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza.

Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 344 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

344

Actual

Start

Jan 2007

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
BioCryst PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for patients with flu who also have a fever as well as other flu symptoms. Patients must have had symptoms for less than 48 hours in order to participate. Patients will have two out of three chances of getting an active study treatment and the other third will receive a placebo (dummy drug). Nobody will know who gets the active drug and who gets the inactive drug. All patients will get supplies to treat symptoms of flu. Patients will need to be seen 5 more times after they are enrolled in the study.

Conditions

  • Influenza

Interventions

  • Peramivir 150 mgDrug

    Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).

  • Peramivir 300 mgDrug

    Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).

  • PlaceboDrug

    Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Alleviation of Symptoms (Kaplan-Meier Estimate)Time frame: Up to 14 days

Locations

69 sites in 2 countries. Site status is shown where the registry gives one.

  • Radiant Research

    Birmingham, Alabama

  • Clopton Clinic

    Jonesboro, Arkansas

  • Advanced Clinical Research Institute

    Anaheim, California

  • Orange County Clinical Trials

    Anaheim, California

  • Medical Center

    Carmichael, California

  • Pacific Sleep Medicines Service

    El Centro, California

  • Advanced Clinical Research Institute

    Orange, California

  • Benchmark Research

    Sacramento, California

  • Pacific Sleep Medicine Services

    San Diego, California

  • Pacific Sleep Medicine Services

    San Francisco, California

  • Alpine Clinical Research Center

    Boulder, Colorado

  • George Washington Unviersity

    Washington D.C., District of Columbia

  • Clinical Research of Southern Florida

    Coral Gables, Florida

  • University Clinical Research-Deland, LLC

    DeLand, Florida

  • Florida Medical Research Institute

    Gainesville, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Clinical Research Center

    Sarasota, Florida

  • Palm Beach Research Center

    West Palm Beach, Florida

  • Georgia Clinical Research

    Atlanta, Georgia

  • Wishard Hospital

    Indianapolis, Indiana

  • Radiant Research

    Overland Park, Kansas

  • Kentucky Pediatric / Adult Research

    Bardstown, Kentucky

  • Central Kentucky Research Assoc, Inc

    Lexington, Kentucky

  • Benchmark Research

    Metairie, Louisiana

  • Radiant Research, Minneapolis

    Edina, Minnesota

  • Barnes-Jewish Hospital Emergency Department

    St Louis, Missouri

  • Medex Healthcare Research, Inc.

    St Louis, Missouri

  • Radiant Research

    St Louis, Missouri

  • Bozeman Urgent Care Center

    Bozeman, Montana

  • Alliance Medical Center

    Alliance, Nebraska

  • Midwest Family Physicians

    Omaha, Nebraska

  • UMDNJ

    Cherry Hill, New Jersey

  • Pulmonary & Critical Care Associates

    East Brunswick, New Jersey

  • Brooklyn Hospital Center

    Brooklyn, New York

  • Wake Research Associates, LLC

    Raleigh, North Carolina

  • Summa Health

    Akron, Ohio

  • Sterling Research Group, LTD.

    Cincinnati, Ohio

  • Integrated Medical Research, PC

    Ashland, Oregon

  • Research Across America at Oyster Point Family Health Center

    Lancaster, Pennsylvania

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.